-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79

Benzinga·08/07/2026 18:38:08
Listen to the news
RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and lowers the price target from $81 to $79.